These findings suggest that the molecular assay by dPCR can be widely implemented to detect BRAF V600E in residual FNA biopsy specimens to improve the management of thyroid nodules harboring BRAF variation in a cost-effective manner. This evidence concerns the gene BRAF and thyroid nodule.